Literature DB >> 9525815

Altered therapy schedules in postoperative treatment of patients with malignant gliomas. Twenty year experience of the Maria Skłodowska-Curie Memorial Center in Kraków, 1973-1993.

B Gliński1, P Dymek, J Skołyszewski.   

Abstract

Results of altered therapy schedules obtained in postoperative treatment of 294 patients with malignant gliomas over last 20 years are presented. During this period 135 patients received Conventional Irradiation and Chemotherapy (CICH), 61 patients received Conventional Irradiation (CI), 59 patients received Split Course High Fractional Dose Irradiation (SCHFDI), and 39 patients received Twice a Day Accelerated Irradiation (TDAI). Actuarial survival rates at 2, 3 and 5 years were 19%, 7%, 0% respectively for patients treated with CICH, and they were 21%, 10%, 0% for CI group, 24%, 12%, 0% for SCHFDI option and 15%, 8%, 0% for TDAI schedule. According to the Cox proportional hazard model, only age was significant factor in prognosis.

Entities:  

Mesh:

Year:  1998        PMID: 9525815     DOI: 10.1023/a:1005760123991

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Superfractionated radiotherapy in grade III, IV intracranial gliomas.

Authors:  C M Ludgate; B G Douglas; P F Dixon; P Steinbok; S M Jackson; G B Goodman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-11       Impact factor: 7.038

2.  Epidemiology of primary central nervous system neoplasms. II. Case-control study.

Authors:  N W Choi; L M Schuman; W H Gullen
Journal:  Am J Epidemiol       Date:  1970-05       Impact factor: 4.897

3.  Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study.

Authors:  D G González; J Menten; D A Bosch; E van der Schueren; D Troost; M C Hulshof; J Bernier
Journal:  Radiother Oncol       Date:  1994-08       Impact factor: 6.280

Review 4.  Intracranial tumors: response and resistance to therapeutic endeavors, 1970-1980.

Authors:  H J Bloom
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-07       Impact factor: 7.038

5.  Survival and quality of life after continuous accelerated radiotherapy of glioblastomas.

Authors:  H Keim; P C Potthoff; K Schmidt; M Schiebusch; A Neiss; K R Trott
Journal:  Radiother Oncol       Date:  1987-05       Impact factor: 6.280

6.  Accelerated fractionation radiotherapy for hospitalized glioblastoma multiforme patients with poor prognostic factors.

Authors:  J C Hernandez; Y Maruyama; R Yaes; H W Chin
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

7.  Treatment of supratentorial high grade gliomas with split course high fractional dose postoperative radiotherapy.

Authors:  V A Marcial-Vega; M D Wharam; S Leibel; A Clark; R Zweig; S E Order
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

8.  Radiation treatment with twice a day fractionation versus conventional fractionation in high grade astrocytoma. A retrospective study.

Authors:  M Bignardi; F Bertoni
Journal:  Acta Oncol       Date:  1987       Impact factor: 4.089

9.  Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial.

Authors:  B Gliński
Journal:  J Neurooncol       Date:  1993-05       Impact factor: 4.130

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  4 in total

1.  Thymidine kinase gene delivery using curcumin loaded peptide micelles as a combination therapy for glioblastoma.

Authors:  Jin Hyeong Park; Jaesik Han; Minhyung Lee
Journal:  Pharm Res       Date:  2014-08-27       Impact factor: 4.200

2.  Asterosaponin 1, a cytostatic compound from the starfish Culcita novaeguineae, functions by inducing apoptosis in human glioblastoma U87MG cells.

Authors:  Guang Cheng; Xiang Zhang; Hai-Feng Tang; Yun Zhang; Xin-Hai Zhang; Wei-Dong Cao; Da-Kuan Gao; Xi-Ling Wang; Bo-quan Jin
Journal:  J Neurooncol       Date:  2006-04-21       Impact factor: 4.130

3.  Opuntia humifusa partitioned extracts inhibit the growth of U87MG human glioblastoma cells.

Authors:  Sahng-Wook Hahm; Jieun Park; Yong-Suk Son
Journal:  Plant Foods Hum Nutr       Date:  2010-09       Impact factor: 3.921

4.  Characterization of invading glioma cells using molecular analysis of leading-edge tissue.

Authors:  Cheol-Soo Kim; Shin Jung; Tae-Young Jung; Woo-Youl Jang; Heung-Suk Sun; Hyang-Hwa Ryu
Journal:  J Korean Neurosurg Soc       Date:  2011-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.